PTC Therapeutics (PTCT) Misses Q1 EPS by 40c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Join SI Premium – FREE
PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.88), $0.40 worse than the analyst estimate of ($1.48). Revenue for the quarter came in at $220.4 million versus the consensus estimate of $205.47 million.
GUIDANCE:
PTC Therapeutics sees FY2023 revenue of $0.94-1 billion vs $0.87 billion estimate.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ScanSource (SCSC) Misses Q1 EPS by 25c ; Offers Guidance
- Gildan Activewear (GIL) Misses Q3 EPS by 3c ; Offers Guidance
- Appian Corporation (APPN) Tops Q3 EPS by 18c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
